Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Large Growth in Short Interest

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 12,685,342 shares, an increase of 87.3% from the January 15th total of 6,772,644 shares. Based on an average daily volume of 5,603,339 shares, the days-to-cover ratio is currently 2.3 days. Currently, 4.9% of the company’s stock are short sold. Currently, 4.9% of the company’s stock are short sold. Based on an average daily volume of 5,603,339 shares, the days-to-cover ratio is currently 2.3 days.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Ted C. Nark sold 50,000 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $11.72, for a total value of $586,000.00. Following the completion of the transaction, the director owned 291,029 shares in the company, valued at approximately $3,410,859.88. This represents a 14.66% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 26.56% of the company’s stock.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AMRX. Spire Wealth Management increased its position in Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Intech Investment Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company’s stock valued at $1,229,000 after buying an additional 1,159 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Amneal Pharmaceuticals by 2.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company’s stock worth $859,000 after acquiring an additional 1,582 shares during the period. Comerica Bank raised its position in Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company’s stock worth $59,000 after acquiring an additional 1,685 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after acquiring an additional 2,168 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on AMRX. Piper Sandler restated an “overweight” rating and issued a $13.00 price objective (up previously from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial set a $15.00 target price on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Finally, Barclays assumed coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price target on the stock. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX opened at $14.63 on Friday. The stock has a market capitalization of $4.60 billion, a P/E ratio of 731.87 and a beta of 1.36. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $15.00. The company’s fifty day moving average is $13.23 and its two-hundred day moving average is $11.23.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.